NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
http://www.reportlinker.com/p0110533/Daiichi-Sankyo-Co-Ltd-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Daiichi Sankyo's performance against key rivals in the prescription pharmaceutical sector
*Assess the importance of Daiichi Sankyo's olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) to the company's outlook
*Evaluate the prospects of the company's recent acquisition, Ranbaxy
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly update 3
Company Introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Daiichi Sankyo: PharmaVitae forecasts at a glance 8
Strategic insight 9
Olmesartan franchise central to Daiichi Sankyo's growth over 2002-14 9
Successful prevention of generic threat 9
Ranbaxy acquisition to drive growth over 2008-14 9
SWOT analysis 11
Strengths 11
Successful line extensions have propelled Daiichi Sankyo to a leading position in the antihypertensives market 11
Strong connections with US pharma 12
Weaknesses 12
Lack of portfolio diversity 12
Opportunities 12
Ranbaxy acquisition provides significant growth prospects and opportunities for streamlining 12
Effient to provide significant royalty income 13
Threats 13
Ranbaxy regulatory scrutiny by FDA 13
TABLE OF CONTENTS 14
Table of figures 16
Chapter 3 Quarterly update 17
Latest comment 17
Q3 2009 17
Q2 2009 17
Biota: new flu drug may present Tamiflu alternative 17
Prasugrel: a flawed approval? 18
Q1 2009 20
Latest prescription pharma product news 21
Q1 2010 21
Q4 2009 21
Q3 2009 22
Q2 2009 23
Q1 2009 24
Q4 2008 25
Latest corporate news 26
Q4 2009 26
Q3 2009 26
Q2 2009 26
Q1 2009 26
Q4 2008 26
Chapter 4 Company Introduction 28
Key findings 28
Background 29
M&A history 29
Ranbaxy acquisition 29
Zenotech: opportunity in biopharmaceuticals 30
Current corporate structure 31
Chapter 5 Company sales 32
Key findings 32
Prescription pharmaceutical sales and growth rate analysis, 2002-14 33
Product analysis 35
Product analysis, 2002-08 36
Product analysis, 2008-14 38
Therapy area analysis 42
Geographic analysis 44
Launch/core/expiry analysis 47
Explanation of launch/core/expiry analysis 47
Launch analysis, 2008-14 48
Core analysis, 2008-14 49
Expiry analysis, 2008-14 50
Generics analysis, 2008-14 51
Launch/core/expiry configuration, 2008-14 52
Molecule type analysis 53
Externalization analysis 55
Chapter 6 Appendix 58
Abbreviations 58
Exchange rates 59
About Datamonitor 60
About Datamonitor Healthcare 60
Datamonitor consulting 60
Disclaimer 62
LIST OF TABLES
Table 1: Daiichi Sankyo - PharmaVitae forecasts at a glance 8
Table 2: Daiichi Sankyo product portfolio overview ($m), 2002-08 36
Table 3: Daiichi Sankyo product portfolio overview ($m), 2008-14 38
Table 4: Daiichi Sankyo prescription pharmaceutical sales by therapy area ($m), 2008-14 43
Table 5: Daiichi Sankyo prescription pharmaceutical sales by geographic region ($m), 2008-14 45
Table 6: Daiichi Sankyo launch portfolio overview ($m), 2008-14 48
Table 7: Daiichi Sankyo core portfolio overview ($m), 2008-14 49
Table 8: Daiichi Sankyo expiry portfolio overview ($m), 2008-14 50
Table 9: Daiichi Sankyo generics portfolio overview ($m), 2008-14 51
Table 10: Daiichi Sankyo prescription pharmaceutical sales by molecule type ($m), 2008-14 54
Table 11: Daiichi Sankyo prescription pharmaceutical sales by source ($m), 2008-14 56
Table 12: Exchange rates, 2009 59
LIST OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Daiichi Sankyo's financial performance ($m), 2002-14 7
Figure 4: Daiichi Sankyo sales according to key growth drivers ($m), 2002-14, 10
Figure 5: Daiichi Sankyo SWOT analysis 11
Figure 6: Current corporate structure 31
Figure 7: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 33
Figure 8: Key product sales ($m), 2002-14 35
Figure 9: Daiichi Sankyo key sales growth drivers and resistors ($m), 2002-08 37
Figure 10: Daiichi Sankyo key sales growth drivers and resistors ($m), 2008-14 40
Figure 11: Daiichi Sankyo prescription pharmaceutical sales by therapy area ($m), 2002-14 42
Figure 12: Daiichi Sankyo prescription pharmaceutical sales by geographic region ($m), 2002-14 44
Figure 13: Daiichi Sankyo launch/core/expiry configuration ($m), 2008-14 52
Figure 14: Daiichi Sankyo prescription pharmaceutical sales by molecule type ($m), 2002-14 53
Figure 15: Daiichi Sankyo prescription pharmaceutical sales by source ($m), 2002-14 55
To order this report:
Pharmaceutical Industry: Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Check our Company Profile, SWOT and Revenue Analysis!
SOURCE Reportlinker